Evotec SE's revenue for the
three
months ended in Mar. 2026 was CHF142.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was CHF692.7 Mil.
Evotec SE's Revenue per Share for the
three
months ended in Mar. 2026 was CHF0.80.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF3.90.
Warning Sign:
Evotec SE revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Evotec SE was -5.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 16.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Evotec SE's highest 3-Year average Revenue per Share Growth Rate was 40.00% per year. The lowest was -30.40% per year. And the median was 12.20% per year.
Evotec SE (XSWX:EVT) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Evotec SE Revenue Related Terms
Evotec SE Revenue Historical Data
* Premium members only.
The historical data trend for Evotec SE's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Revenue distribution charts can be found below:
* The bar in red indicates where Evotec SE's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF692.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (XSWX:EVT) has a Revenue of CHF692.7 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Evotec SE and its competitors.
Is Evotec SE's Revenue too high?
Evotec SE's current Revenue is CHF692.7 Mil. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Revenue compare to ZTS and UTHR?
Evotec SE's Revenue of CHF692.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Evotec SE and its competitors. Evotec SE's current Revenue is CHF692.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Revenue is CHF692.7 Mil. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Revenue is CHF692.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
Revenue: CHF692.7 Mil
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
